|Dr. Corey S. Goodman||Independent Exec. Chairman||38.5k||N/A||1952|
|Dr. Jaume Pons Ph.D.||Pres, CEO & Director||1.28M||N/A||1966|
|Mr. Peter S. Garcia||Chief Financial Officer||817.65k||N/A||1962|
|Dr. Sophia Randolph M.D., Ph.D.||Chief Medical Officer & Director||938.5k||N/A||1968|
|Dr. Michael Chang Ph.D.||VP of Operations||N/A||N/A||N/A|
|Ms. Shelly Pinto||VP of Fin. & Chief Accounting Officer||N/A||N/A||1976|
|Dr. Michael Warner J.D., Ph.D.||Gen. Counsel||N/A||N/A||N/A|
|Ms. Jeanne Y. Jew||Chief Bus. Officer||N/A||N/A||1964|
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer. The company's pre-clinical products include SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was incorporated in 2015 and is based in Burlingame, California.
ALX Oncology Holdings Inc.’s ISS Governance QualityScore as of June 1, 2021 is 8. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 8; Compensation: 9.